AbbVie Partners with Simcere Zaiming to Develop Novel Trispecific Antibody for Multiple Myeloma

AbbVie and Simcere Zaiming have signed an OTL agreement regarding the joint development of SIM0500, an investigator-ready trispecific antibody for relapsed/refractory MM. About SIM0500 is developed with the T-cell engager technology by Simcere Zaiming, and it targets GPRC5D, BCMA, and CD3 to increase T-cell cytotoxicity against MM cells applying multiple antitumor procedures. This underlines AbbVie’s continuing obligation towards the progress of unique cancer drugs.

Simcere Zaiming will secure an initial payment and is entitled to additional payments up to $1.055 billion in milestones and various escalating royalty rates based on net sales outside Greater China. From the financial modeling, this has indicated that AbbVie is poised to earn royalties within Greater China as the strategic partnership embodies the best solution for both stakeholders to meet important unmet needs for the treatment of MM. The two firms expect to take SIM0500 a notch higher as the world seeks a new kind of treatment for multiple myeloma patients.